SELLAS Life Sciences Group, Inc.
Initiate a Phase 2a clinical trial of GFH009
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 Mar 2023
- Due
- 30 Jun 2023
- Delivered
- Q2 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The primary endpoint of the Phase 2a clinical trial, which SELLAS expects to initiate during the second quarter of 2023”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2a clinical trial of SLS009 (formerly GFH009) in the second quarter of 2023, meeting its stated commitment.
-
A SELLAS Life Sciences Group, Inc. 8-K filed 2023-08-10
“First Patients Dosed in Phase 2a Clinical Trial of SLS009 (formerly GFH009) in Acute Myeloid Leukemia” ✓ confirmed on the page
-
A SELLAS Life Sciences Group, Inc. 10-K filed 2024-03-28
“In the second quarter of 2023, we commenced an open label, single arm, multi-center Phase 2a clinical trial of SLS009 in combination with aza/ven” ✓ confirmed on the page
Market reaction: the shares moved -3.7% against the S&P 500 over the three sessions around the disclosure (9 Aug 2023 to 14 Aug 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2a clinical trial of GFH009
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-SLS-002006 · Corrections policy